摘要:
An ophthalmic laser treatment apparatus comprises: a laser source that emits a laser beam for treatment of an affected part of a patient's eye; an optical fiber that transmits the laser beam emitted from the laser source; and a delivery optical system that irradiates the laser beam emitted from the optical fiber to the affected part of the patient's eye, the delivery optical system including: a plurality of diffraction optical elements each being configured to shape a beam profile of the laser beam at an emission end face of the optical fiber into a beam profile having one of a uniform intensity and a lower intensity in the center than on the periphery on the affected part and also to shape the laser beam to have a different spot size on the affected part of the patient's eye; and a changing unit which selectively disposing one of the diffraction optical elements on an optical path.
摘要:
A main body controller provided in an image forming apparatus receives a VDP job from an external computer, and arranges image data of a reusable object and a variable object, which correspond to the VDP job, on a page for printout. An inspection controller performs inspection processing for printed matter for each page, and the main body controller preferentially stores image data of the reusable object, which corresponds to the page for which the printing has been determined to be defective as a result of inspection processing, in a cache unit. The main body controller acquires the reusable object, which corresponds to the page for which the printing has been determined to be defective, from the cache unit, and executes page reprint processing using the acquired reusable object.
摘要:
An iris authentication apparatus includes an iris area extraction unit, registration pattern generating unit, collation pattern generating unit, and collation unit. The iris area extraction unit extracts iris areas from a sensed registration eyeball image and a sensed collation eyeball image. When the iris area extraction unit extracts an iris area from the registration eyeball image, the registration pattern generating unit generates a registration iris pattern image by performing polar coordinate transformation of an image in the extracted iris area. When the iris area extraction unit extracts an iris area from the collation eyeball image, the collation pattern generating unit generates a collation iris pattern image by performing polar coordinate transformation of an image in the extracted iris area. The collation unit collates the registration iris pattern image output from the registration pattern generating unit and the collation iris pattern image output from the collation pattern generating unit on the basis of a correlation therebetween.
摘要:
A switching DC-DC converter includes: an output voltage detecting unit configured to detect a DC output voltage; an error amplifying unit configured to compare the detected output voltage and a reference voltage and configured to supply an amplified error signal between the detected output voltage and the reference voltage to the pulse width modulating unit; and a single oscillating unit connected to an output of the output voltage detecting unit and an output of the error amplifying unit and operable on a first oscillating mode and a second oscillation mode. The oscillating unit on the first oscillating mode controls a switching frequency of the power switch based on the detected output voltage. The oscillating unit on the second oscillating mode controls the switching frequency of the power switch based on the amplified error signal.
摘要:
The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
摘要:
The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
摘要:
The present invention relates to a process for preparing a compound of formula (6a): wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Ar2 represents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and R11 represents a group selected from certain substituents.
摘要翻译:本发明涉及式(6a)化合物的制备方法:其中Ar 1表示可被1〜3个取代基取代的咪唑基, Ar 2表示吡啶基,嘧啶基或可被1〜3个取代基取代的苯基; R 11表示选自某些取代基的基团。
摘要:
The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single bond, an optionally substituted C1-6 alkylene group etc.; and A indicates an optionally substituted C6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
摘要:
The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.
摘要:
A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13C solid NMR spectrum.